Tissue inhibitor of metalloproteinases-1-induced scattered liver metastasis is mediated by host-derived urokinase-type plasminogen activator

被引:21
|
作者
Schroetzlmair, Florian [1 ]
Kopitz, Charlotte [1 ]
Halbgewachs, Birgit [1 ]
Lu, Fei [1 ]
Alguel, Hana [2 ]
Brunner, Nils [3 ]
Gaensbacher, Bernd [1 ]
Krueger, Achim [1 ]
机构
[1] Tech Univ Munich, Inst Expt Onkol & Therapieforsch, Klinikum Rechts Isar, D-81675 Munich, Germany
[2] Tech Univ Munich, Med Klin & Poliklin 2, Klinikum Rechts Isar, D-81675 Munich, Germany
[3] Inst Vet Patobiol, Frederiksberg, Denmark
关键词
TIMP-1; uPA; HGF; scattering; liver metastasis; protease web; HEPATOCYTE GROWTH-FACTOR; BREAST-CANCER; MATRIX METALLOPROTEINASES; RETROVIRAL VECTORS; GENE-EXPRESSION; XENOGRAFT MODEL; MET RECEPTOR; CYSTATIN-C; HIGH-TITER; LYMPHOMA;
D O I
10.1111/j.1582-4934.2009.00951.x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Paradoxically, not only proteinases but also their inhibitors can correlate with bad prognosis of cancer patients, underlining the evolving concept of the protease web as the complex interplay between proteinases, their inhibitors and effector molecules. Elevated levels of tissue inhibitor of metalloproteinases-1 (TIMP-1) render the liver more susceptible to metastasis by triggering urokinase plasminogen activator (uPA) expression as well as hepatocyte growth factor (HGF) signalling, thereby leading to the fatal scattered infiltration of metastasizing tumour cells throughout the parenchyma of the target organ. Here, we investigated whether host uPA is a crucial protagonist for the TIMP-1-induced modulation of a pro-metastatic microenvironment in the liver. Indeed, in livers of uPA-ablated mice elevated TIMP-1 levels did not trigger HGF signalling and did not promote metastasis of a murine T-lymphoma cell line. In contrast, lack of tumour cell-derived uPA induced by gene silencing did not interfere with this pro-metastatic pathway. Furthermore, host uPA was necessary for the recruitment of neutrophilic granulocytes and the associated increase of HGF in livers with elevated TIMP-1 levels. This newly identified co-operation between TIMP-1 and host uPA suggests that therapies, simultaneously interfering with pro- and anti-proteolytic pathways may be beneficial for patients with metastatic disease.
引用
收藏
页码:2760 / 2770
页数:11
相关论文
共 40 条
  • [21] Regulation of plasminogen activator inhibitor-1 secretion by urokinase and tissue plasminogen activator in rat epithelioid-type smooth muscle cells
    Lau, HKF
    Ho, J
    BRITISH JOURNAL OF HAEMATOLOGY, 2002, 117 (01) : 151 - 158
  • [22] Structure-based design of an urokinase-type plasminogen activator receptor-derived peptide inhibiting cell migration and lung metastasis
    Carriero, Maria Vincenza
    Longanesi-Cattani, Immacolata
    Bifulco, Katia
    Maglio, Ornella
    Lista, Liliana
    Barbieri, Antonio
    Votta, Giuseppina
    Masucci, Maria Teresa
    Arra, Claudio
    Franco, Renato
    De Rosa, Mario
    Stoppelli, Maria Patrizia
    Pavone, Vincenzo
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (09) : 2708 - 2717
  • [23] The plasminogen activation system in skeletal muscle regeneration: Antagonistic roles of urokinase-type plasminogen activator (UPA) and its inhibitor (PAI-1)
    Suelves, M
    Vidal, B
    Ruiz, V
    Baeza-Raja, B
    Diaz-Ramos, A
    Cuartas, I
    Lluis, F
    Parra, M
    Jardi, M
    Lopez-Alemany, R
    Serrano, AL
    Munoz-Canoves, P
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2005, 10 : 2978 - 2985
  • [24] LIM kinase 1 increases tumor metastasis of human breast cancer cells via regulation of the urokinase-type plasminogen activator system
    Bagheri-Yarmand, R
    Mazumdar, A
    Sahin, AA
    Kumar, R
    INTERNATIONAL JOURNAL OF CANCER, 2006, 118 (11) : 2703 - 2710
  • [25] Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients
    de Witte, JH
    Sweep, CGJ
    Klijn, JGM
    Grebenschikov, N
    Peters, HA
    Look, MP
    van Tienoven, TH
    Heuvel, JJTM
    van Putten, WLJ
    Benraad, TJ
    Foekens, JA
    BRITISH JOURNAL OF CANCER, 1999, 79 (7-8) : 1190 - 1198
  • [26] Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients
    J H de Witte
    C G J Sweep
    J G M Klijn
    N Grebenschikov
    H A Peters
    M P Look
    Th H van Tienoven
    J J T M Heuvel
    W L J van Putten
    Th J Benraad
    J A Foekens
    British Journal of Cancer, 1999, 79 : 1190 - 1198
  • [27] Involvement of matrix metalloproteinase 1 and urokinase-type plasminogen activator in the PKCα-p38 MAPK pathway-mediated progression of human liver cancer cells
    Ye, Je-Chiuan
    Hsieh, Yih-Shou
    Chen, Pei-Ni
    Liu, Jer-Yuh
    Hsieh, Yi-Hsien
    DRUG DEVELOPMENT RESEARCH, 2023, 84 (04) : 767 - 776
  • [28] Expression of Urokinase-Type Plasminogen Activator (uPA), its Receptor (uPAR), and Inhibitor (PAI-1) in Human Breast Carcinomas and Their Clinical Relevance
    Andres, Sarah A.
    Edwards, Angelena B.
    Wittliff, James L.
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2012, 26 (02) : 93 - 103
  • [29] Clinical Significance of Urokinase-type Plasminogen Activator (uPA) and its Type-1 Inhibitor (PAI-1) for Metastatic Sentinel Lymph Node Involvement in Breast Cancer
    Harms, Wibke
    Malter, Wolfram
    Kraemer, Stefan
    Drebber, Uta
    Drzezga, Alexander
    Schmidt, Matthias
    ANTICANCER RESEARCH, 2014, 34 (08) : 4457 - 4462
  • [30] External quality assessment of trans-European multicentre antigen determinations (enzyme linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts
    Sweep, CGJ
    Geurts-Moespot, J
    Grebenschikov, N
    de Witte, JH
    Heuvel, JJTM
    Schmitt, M
    Duffy, MJ
    Jänicke, F
    Kramer, MD
    Foekens, JA
    Brünner, N
    Brugal, G
    Pedersen, AN
    Benraad, TJ
    BRITISH JOURNAL OF CANCER, 1998, 78 (11) : 1434 - 1441